Congratulations to Wafa for passing her Preliminary Qualifying Exam for the Harvard BBS Program today!
Aaron speaks at the University of Colorado Cancer Center. Thank you to Dr. Sabrina Spencer for hosting. A great opportunity to make new friends and reconnect with former colleagues and trainees!
Check out a new manuscript
“Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction” now posted to bioRxiv! This is the product of a terrific collaboration with the
Weiskopf lab at MIT.
Drilon A, Horan JC, Tangpeerachaikul A, Besse B, Ou SI, Gadgeel SM, Camidge DR, van der Wekken AJ, Nguyen-Phuong L, Acker A, Keddy C, Nicholson KS, Yoda S, Mente S, Sun Y, Soglia JR, Kohl NE, Porter JR, Shair MD, Zhu V, Davare MA, Hata AN, Pelish HE, Lin JJ. NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations. Cancer Discovery. 2023 Mar 1;13(3):598-615. doi: 10.1158/2159-8290.PMID: 36511802